electroCore, Inc, a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions.

商用阶段的生物电子技术公司 electroCore, Inc 今天宣布完成与 NeuroMetrix, Inc（“NeuroMetrix”或“NURO”）(纳斯达克股票代码：NURO) 的合并（“合并”），将自身定位为非侵入性健康和保健解决方案的多元化领导者。

The acquisition of NeuroMetrix’s Quell® Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chronic pain and wellness conditions..

NeuroMetrix的Quell®纤维肌痛解决方案的收购扩大了electroCore的非侵入性生物电子治疗产品组合，增强了其商业影响力——尤其是在退伍军人医院系统内——并且预计将大幅增加其针对慢性疼痛和健康状况的可治疗市场。

Dan Goldberger, CEO of electroCore, Inc. commented, 'With this transaction now closed, we are well-positioned to immediately leverage our established distribution channels, particularly within the VA Hospital System, to accelerate adoption of the Quell Fibromyalgia solution. This addition meaningfully expands our addressable market and diversifies our portfolio of non-pharmaceutical, non-invasive nerve stimulation offerings, strengthening electroCore’s position as a leading publicly traded bioelectronic technology platform focused on wellness and chronic pain management.'.

electroCore, Inc.首席执行官丹·戈德伯格评论道：“随着本次交易的完成，我们已准备好立即利用我们既有的分销渠道，特别是在退伍军人医院系统内，加速Quell纤维肌痛解决方案的推广。这一新增内容显著扩展了我们的可覆盖市场，并丰富了我们非药物、非侵入性神经刺激产品组合，巩固了electroCore作为专注于健康与慢性疼痛管理的领先公开交易生物电子技术平台的地位。”

Under the terms of the Merger Agreement dated December 17, 2024 and approved by NeuroMetrix’s stockholders at a Special Meeting held on March 21, 2025:

根据2024年12月17日签署的合并协议条款，并经NeuroMetrix股东在2025年3月21日举行的特别会议上批准：

Each share of NURO common stock, outstanding immediately prior to the closing was converted into the right to receive (i) a cash payment of $4.49 per share and (ii) one contingent value right (CVR).

紧接收盘前已发行的每股NURO普通股被转换为获得以下权利：(i) 每股4.49美元的现金支付；以及 (ii) 一项或有价值权（CVR）。

The CVRs entitle holders to contingent cash payments based on the achievement of certain sales milestones tied to the Quell business as well as future proceeds from the disposition of NURO’s DPNCheck business, subject to the terms outlined in the CVR agreement dated May 1, 2025.

CVRs 赋予持有者基于 Quell 业务相关销售里程碑的达成情况获得有条件现金支付的权利，同时也包括未来 NURO 出售 DPNCheck 业务的收益，具体受 2025 年 5 月 1 日签订的 CVR 协议条款约束。

As a result of the Merger, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, and NURO’s shares will be de-listed from the Nasdaq Capital Market prior to the opening of trading on May 2, 2025.

由于此次合并，NeuroMetrix成为electroCore的间接全资子公司，NURO的股票将在2025年5月2日交易开始前从纳斯达克资本市场退市。

Additional information on the transaction can be found in a Current Report on Form 8-K filed by electroCore, Inc. with the SEC.

有关该交易的更多信息，请参阅 electroCore, Inc. 向美国证券交易委员会提交的 8-K 表格当前报告。

About electroCore, Inc.

关于electroCore公司。

electroCore, Inc. and its subsidiaries are a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.  For more information, visit www.electrocore.com.

electroCore, Inc. 及其子公司是一家处于商业化阶段的生物电子技术公司，其使命是通过创新的非侵入性生物电子技术改善健康和生活质量。欲了解更多信息，请访问 www.electrocore.com。

Forward-Looking Statements

前瞻性声明

This press release may contain forward-looking statements within the meaning of the federal securities laws, including under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of the merger with NeuroMetrix, Inc., electroCore's business prospects, its product portfolio or potential markets for its technologies, and other statements that are not historical in nature, particularly those using terminology such as 'anticipates,' 'expects,' 'believes,' 'intends,' other words of similar meaning, derivations of such words and the use of future dates.

本新闻稿可能包含根据联邦证券法，包括1995年私人证券诉讼改革法案所定义的前瞻性陈述。这些前瞻性陈述包括但不限于关于与NeuroMetrix, Inc.合并的预期收益、electroCore的业务前景、其产品组合或技术潜在市场的陈述，以及其他非历史性质的陈述，特别是那些使用“预期”、“预计”、“相信”、“打算”等术语及其他具有类似含义的词语及其衍生词和未来日期的陈述。

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize nVNS products, competition in the industry in which electroCore operates and general market conditions.

由于众多因素，实际结果可能与任何前瞻性声明中预测的结果有所不同。这些因素包括但不限于：获得继续经营 electroCore 业务、销售和营销以及产品开发计划所需的额外融资的能力；开发新产品或技术所固有的不确定性；成功将 nVNS 产品商业化的可能性；electroCore 所处行业的竞争态势以及总体市场状况。

Important risk factors that may cause such a difference include, but are not limited to: (i) the anticipated tax treatment of the transaction may not be obtained, (ii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the businesses of NeuroMetrix and electroCore after the consummation of the transactions, (iii) potential litigation relating to the proposed transaction that coul.

可能导致此类差异的重要风险因素包括但不限于：(i) 交易预期的税务处理可能无法实现，(ii) 未预见负债、未来资本支出、收入、成本、费用、收益、协同效应、经济表现、债务、财务状况和损失对NeuroMetrix和electroCore在交易完成后业务及管理策略的未来发展、管理和扩展的影响，(iii) 与拟议交易相关的潜在诉讼。

Contact

联系

ECOR Investor Relations

ECOR投资者关系

(973) 302-9253

(973) 302-9253

[email protected]

[email protected]

Source: electrocore.com

来源：electrocore.com